← Back to Clinical Trials
Recruiting NCT05792930

NCT05792930 Developing an Integrated Psychotherapy With Cognitive-behavioral Therapy and Biofeedback Therapy for Somatic Symptom Disorder

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05792930
Status Recruiting
Phase
Sponsor National Taiwan University Hospital
Condition Somatic Symptom Disorder
Study Type INTERVENTIONAL
Enrollment 60 participants
Start Date 2023-07-11
Primary Completion 2026-06-30

Eligibility & Interventions

Sex All sexes
Min Age 20 Years
Max Age 70 Years
Study Type INTERVENTIONAL
Interventions
cognitive-behavioral therapy and biofeedback therapy

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 60 participants in total. It began in 2023-07-11 with a primary completion date of 2026-06-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This research program is aimed to develop a integrative psychotherapy (including CBT and biofeedback therapy) and to examine its efficacy on treatment of somatic symptom disorder. The study design is a randomized controlled trial with waiting list control. Scores of Patient Health Questionniare-15 and Health Anxiety Questionnaire are the primary endpoints.

Eligibility Criteria

Inclusion Criteria: * Patient with somatic symptom disorder (confirmed by psychiatrists) Exclusion Criteria: * The age is younger than 20 or older than 70 years * Having psychotic symptoms or cognitive impairment * Having a potentially lethal illness * Cannot read the questionnaires by oneself

Contact & Investigator

Central Contact

Wei-Lieh Huang, MD, PhD

✉ weiliehhuang@gmail.com

📞 886-5-5323911

Principal Investigator

Wei-Lieh Huang, MD, PhD

PRINCIPAL INVESTIGATOR

National Taiwan University Hospital

Frequently Asked Questions

Who can join the NCT05792930 clinical trial?

This trial is open to participants of all sexes, aged 20 Years or older, up to 70 Years, studying Somatic Symptom Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05792930 currently recruiting?

Yes, NCT05792930 is actively recruiting participants. Contact the research team at weiliehhuang@gmail.com for enrollment information.

Where is the NCT05792930 trial being conducted?

This trial is being conducted at Yunlin, Taiwan.

Who is sponsoring the NCT05792930 clinical trial?

NCT05792930 is sponsored by National Taiwan University Hospital. The principal investigator is Wei-Lieh Huang, MD, PhD at National Taiwan University Hospital. The trial plans to enroll 60 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology